Guggenheim Reiterates Buy Rating on Biogen Inc. (BIIB)

Market Context

Biogen Inc. operates in the Healthcare sector. The stock currently trades at $202.92 with a market capitalization of $25.3B. The stock has gained 23.8% over the past 52 weeks.

Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Biogen Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Biogen Inc.

Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 21, 2026	Guggenheim	Buy	N/A
Jul 21, 2026	B of A Securities	Neutral	N/A
Jul 13, 2026	Truist Securities	Buy	N/A
Jul 08, 2026	Morgan Stanley	Equal-Weight	N/A
Jul 07, 2026	RBC Capital	Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View BIIB Stock Page